Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
TCBS Texas Community Bancshares Inc
UPC Universe Pharmaceuticals Inc
MHH Mastech Digital Inc
GCTK GlucoTrack Inc
KODK Eastman Kodak Co
FYBR Frontier Communications Parent Inc
TPNEF Cub Energy Inc
ECC Eagle Point Credit Co LLC
CPHI China Pharma Holdings Inc
Go

Health Care : Biotechnology |
Company profile

Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.

Closing Price
$6.15
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
60,939
0

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centennial Resource Development, Inc. (Nasdaq - CDEV), Rattler Midstream LP (Nasdaq - RTLR), ManTech International Corporation (Nasdaq - MANT), Chardan NexTech Acquisition 2 Corp. (Nasdaq - CNTQ)

10:32 am ET June 9, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:CDEV),(NASDAQ:RTLR),(NASDAQ:MANT),(NASDAQ:CNTQ),(NASDAQ:FANG),(NASDAQ:CG), EQNX::TICKER_END Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Centennial Resource Development, Inc. (Nasdaq - CDEV)

Under the terms of the agreement, Centennial will merge with Colgate Energy Partners III, LLC ("Colgate"). Colgate is valued at approximately $3.9 billion and is the deal is comprised of 269.3 million shares of Centennial stock, $525 million of cash and the assumption of approximately $1.4 billion of Colgate's outstanding net debt. Centennial shareholders will hold approximately 53% of the combined company. The investigation concerns whether the Centennial Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether the deal is fair to Centennial shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/centennial-resource-development-inc-nasdaq-cdev/.

Rattler Midstream LP (Nasdaq - RTLR)

Under the terms of the agreement, Rattler will be acquired by Diamondback Energy, Inc. ("Diamondback") (Nasdaq - FANG). Diamondback will acquire all publicly held common units representing the limited partner interests in Rattler not already owned by Diamondback and its subsidiaries. The agreement provides for an all-stock transaction whereby each public unitholder of Rattler would receive 0.113 of a share of common stock in Diamondback in exchange for each Rattler common unit owned, an implied per-share merger consideration of approximately $15.08 based on Diamondback's May 13, 2022 closing price of $133.43. The investigation concerns whether the Rattler Board breached its fiduciary duties to unitholders by failing to conduct a fair process, and whether Diamondback is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/rattler-midstream-lp-nasdaq-rtlr/.

ManTech International Corporation (Nasdaq - MANT)

Under the terms of the agreement, ManTech will be acquired by funds managed by global investment firm Carlyle (Nasdaq - CG) in an all-cash transaction with a total enterprise value of approximately $4.2 billion. ManTech shareholders will receive $96.00 per share in cash for each share of ManTech they own. The investigation concerns whether the ManTech Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Carlyle is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/mantech-international-corporation-nasdaq-mant/.

Chardan NexTech Acquisition 2 Corp. (Nasdaq - CNTQ)

Under the terms of the agreement, Chardan, a special purpose acquisition company, will combine with Dragonfly Energy Corp. ("Dragonfly"), a leader in energy storage and producer of deep cycle lithium-ion storage batteries, and result in Dragonfly becoming a publicly-listed company. Under the terms of the agreement, Chardan shareholders will retain ownership of only 23% of the combined company. The investigation concerns whether the Chardan Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

Additional information can be found at visit https://www.brodskysmith.com/cases/chardan-nextech-acquisition-2-corp-nasdaq-cntq/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png

https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png

comtex tracking

COMTEX_408436833/2010/2022-06-09T10:32:27

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.